Mesoblast (NASDAQ:MESO) Shares Gap Down – Should You Sell?

Mesoblast Limited (NASDAQ:MESO)’s stock price gapped down before the market opened on Tuesday . The stock had previously closed at $14.87, but opened at $13.88. Mesoblast shares last traded at $13.7960, with a volume of 101,995 shares changing hands.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Mesoblast in a research note on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold”.

Mesoblast Stock Performance

The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.41 and a current ratio of 1.58. The firm’s 50 day moving average is $15.97 and its 200-day moving average is $16.88. The firm has a market cap of $1.74 billion, a price-to-earnings ratio of -15.37 and a beta of 2.19.

Mesoblast (NASDAQ:MESO) last released its quarterly earnings data on Thursday, January 29th. The company reported ($0.16) earnings per share (EPS) for the quarter. The company had revenue of $25.67 million for the quarter. Sell-side analysts anticipate that Mesoblast Limited will post -0.7 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Mesoblast

Several institutional investors and hedge funds have recently modified their holdings of MESO. Goldman Sachs Group Inc. acquired a new stake in shares of Mesoblast in the 1st quarter valued at $3,209,000. Creative Planning bought a new position in Mesoblast in the 2nd quarter worth $141,000. Raymond James Financial Inc. bought a new position in Mesoblast in the 2nd quarter worth $86,000. China Universal Asset Management Co. Ltd. raised its holdings in Mesoblast by 33.7% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 9,124 shares of the company’s stock worth $99,000 after acquiring an additional 2,302 shares during the period. Finally, Farther Finance Advisors LLC bought a new position in Mesoblast in the 3rd quarter worth $58,000. Institutional investors and hedge funds own 1.43% of the company’s stock.

About Mesoblast

Mesoblast Limited is a global leader in allogeneic cellular medicines, focused on developing treatments for inflammatory and immunologic diseases. Founded in 2004 by Dr. Silviu Itescu, the company builds on proprietary mesenchymal lineage cell technology to create off-the-shelf, donor-derived therapies. These therapies are designed to modulate immune responses and promote tissue repair in conditions where existing medical options are limited or ineffective.

The company’s most advanced product, Alofisel® (darvadstrocel), has been approved in Europe for the treatment of complex perianal fistulas in adults with Crohn’s disease.